First androgen receptor mRNA antagonist enters clinical trials for CRPC

Over the past 5 or so years we have seen a remarkable growth in the diversity of pharmaceuticals being developed for the treatment of more advanced forms of prostate cancer, and there is no sign of a slow-down yet. … READ MORE …

The Thursday news reports: February 27, 2009

In news from sources other than the Genitourinary Cancer Symposium today, we have six reports on:

  • Oxidative stress and the development of prostate cancer
  • A review of PSA kinetics in the diagnosis, prognosis, and monitoring of prstate cancer
  • Focal therapy in general and focal cryoablation specifically
  • The relevance of elevated chondroitin sulphate levels and androgen receptor levels to prostate cancer progression … READ MORE …